Download Free Sample
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
PPAR Gamma Agonist Market: Competitive Landscape, Pipeline, and Market Analysis 2024
PPAR Gamma Agonist Market: Competitive Landscape, Pipeline, and Market Analysis 2024
Peroxisome proliferator-activated receptor gamma (PPAR-γ or PPARG), also known as the glitazone reverse insulin resistance receptor, or NR1C3 (nuclear receptor subfamily 1, group C, member 3) is a type II nuclear receptor functioning as a transcription factor that in humans is encoded by the PPARG gene. PPARG is mainly present in adipose tissue, the colon, and macrophages. Two isoforms of PPARG are detected in humans PPAR-γ1, found in nearly all tissues except muscle, and PPAR-γ2, mostly found in adipose tissue and the intestine. PPARG regulates fatty acid storage and glucose metabolism. Mechanism of action (MOA) of PPAR Gamma agonists involves binding to and activating PPAR gamma receptors. Upon activation, PPAR gamma forms a heterodimer with another nuclear receptor called RXR (retinoid X receptor). This PPAR gamma/RXR complex then binds to specific DNA sequences known as PPAR response elements (PPREs) within the promoter regions of target genes.
Once bound to PPREs, the PPAR gamma/RXR complex recruits co-activator proteins, which facilitate the transcription of target genes. These genes are involved in various metabolic processes, including adipogenesis (formation of new fat cells), lipid metabolism, glucose homeostasis, insulin sensitivity, and inflammation. PPAR Gamma Agonist is used in the treatment of endocrine system diseases, diabetes mellitus, glucose metabolism disorder, acute coronary syndrome, digestive system diseases, hyperinsulinism, heart diseases, hypertension, liver diseases, blood coagulation disorder, brain diseases, etc. The rising prevalence of endocrine diseases, diabetes mellitus, and an aging population are the key drivers for the PPAR Gamma Agonist market. For instance, according to the World Health Organization 2023, About 422 million people worldwide have diabetes. Moreover, the development of novel molecules by many market players is coming up to overcome challenges in therapy. For instance, Roche’s Aleglitazar (R1439) for the treatment of diabetes mellitus is under the various stages of clinical studies.
Key Market Developments:
Drugs under the Pipeline for PPAR Gamma Agonist:
Clinical Activity and Developments of PPAR Gamma Agonist:
Till July 2023, more than 30 companies have approximately 32 molecules targeting the many endocrine disorders and diabetes mellitus. For these molecules, more than 105 clinical trials are being conducted and the majority are in phase-2 and phase-3 clinical trials by the players across the globe. For instance,
|
Molecule Name |
Number of Studies |
|
Duvie (Lobeglitazone) |
42 |
|
Aleglitazar (R1439) |
22 |
|
Lipaglyn (Saroglitazar) |
18 |
|
Liovel (Alogliptin/Pioglitazone) |
16 |
|
Avandamet (Rosiglitazone/Metformin) |
15 |
Molecules such as Aleglitazar (R1439) are under development by Roche for the line of treatment for the treatment of cardiovascular disorders and type 2 diabetes mellitus. Moreover, Zydus Lifesciences Lipaglyn (Saroglitazar) for the potential treatment of dyslipidaemias, hypertriglyceridemia, type 2 diabetes mellitus, liver disorders, and polycystic ovary syndrome is under various stages of clinical trials. Many other molecules are under clinical development for diabetes mellitus and many endocrine diseases.
PPAR Gamma Agonists have been identified as potential therapeutic candidates for endocrine system diseases, diabetes mellitus, glucose metabolism disorder, acute coronary syndrome, etc. The increased incidence of various metabolic diseases like lipid, glucose metabolism disorders, type-1 diabetes mellitus, and the rising old age population; Seems to create an opportunity for the future and burgeon the growth of the PPAR Gamma Agonist market. For instance, according to the International Diabetes Federation 2021, around 61 million people in Europe and 73 million people in the Middle East and North Africa are living with diabetes globally. Moreover, with increased R&D activity and government reimbursement policies, modern diagnostic centers are expected to create lucrative opportunities for the PPAR Gamma Agonist market.
Latin America
Europe
Asia Pacific
Middle East
North America
Download Free Sample Report
The indication of Aleglitazar (R1439) is the treatment of cardiovascular disorders, type 2 diabetes mellitus, etc.
Major market players include Chong Kun Dang, Roche, Zydus Lifesci, Daiichi Sankyo, etc are a few leading market players.
Major Indications for PPAR Gamma agonists are used to treat endocrine system diseases, diabetes mellitus, glucose metabolism disorder, coronary syndrome, digestive system diseases, etc.
There are a total of 28 molecules that are in Phase-1, Phase-2, and Phase-3 clinical development.
Key Market Players
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthcare domain, encompassing pharmaceuticals, medical devices, and diagnostics. A graduate in Pharmacy, he possesses a strong foundation in the intricacies of the healthcare sector. He further enhanced his expertise by pursuing an MBA in Pharmaceuticals, equipping him with valuable business acumen. His analytical skills and market insights have contributed to strategic decision-making and enhanced market positioning for various healthcare organizations. Committed to driving innovation and excellence, Muni continues to seek opportunities to improve healthcare delivery through data-driven insights.